Loading company…
Thytech develops Treg cell therapies for transplant rejection, autoimmune diseases, and immune hyperactivation.
Founded in 2014 in Madrid, Thytech is a research organization focused on immune-related diseases, particularly in young patients. It develops cellular therapies using Treg cells derived from thymic tissue. In April 2022, it raised EUR 350,000 led by B-Startup of Banco Sabadell through BStartup Health, with Genesis Biomed and private investors participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in